Molecular landscape of <scp> <i>TP53</i> </scp> mutations in breast cancer and their utility for predicting the response to <scp>HER</scp> ‐targeted therapy in <scp>HER2</scp> amplification‐positive and <scp>HER2</scp> mutation‐positive amplification‐negative patients-Reference-Cited by-同舟云学术

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

Published:2022-04-07 Issue:14 Volume:11 Page:2767-2778
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Liu Binliang¹²^ORCID,Yi Zongbi¹^ORCID,Guan Yanfang³⁴,Ouyang Quchang²,Li Chunxiao⁵,Guan Xiuwen¹^ORCID,Lv Dan¹,Li Lixi¹^ORCID,Zhai Jingtong¹,Qian Haili⁵,Xu Binghe¹^ORCID,Ma Fei¹^ORCID,Zeng Yixin⁶⁷

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya Medical School Central South University Changsha Hunan China

3. Geneplus‐Beijing Institute Beijing China

4. Department of Computer Science and Technology, School of Electronic and Information Engineering Xi'an Jiaotong University Xi'an Shaanxi China

5. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

6. Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

7. Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4652

Reference29 articles.

1. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

2. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

3. HER kinase inhibition in patients with HER2- and HER3-mutant cancers